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Hepatitis B vaccination in human immunodeficiency virus-
infected adults receiving hemodialysis.
Background. The Centers for Disease Control and Preven-
tion (CDC) recommends hepatitis B virus (HBV) immunization
for all hemodialysis (HD) patients because they are at high risk
of infection. Several studies have shown that the development
of protective antibody titers after HBV vaccination is much
lower in HD patients. We hypothesized that human immunod-
eficiency virus (HIV) infection in patients with end-stage renal
disease (ESRD) would further impair the immune response to
hepatitis B vaccination.
Methods. We performed a retrospective cohort study of pa-
tients undergoing long-term hemodialysis from 1990 to 2002 at
the United States-based dialysis facilities of Gambro Corpora-
tion, North America. The response rate defined as an increase
in anti-HBs levels ≥10 mIU/L after a month of the third dose
of HBV vaccination was determined in HIV-infected and a ran-
domly selected group of ESRD patients. The demographic in-
formation, laboratory data, and hepatitis B surface antibody
(anti-HBs) titers were recorded from the Gambro Corporation
database on these patients.
Results. Of the 347 adult HIV ESRD patients, 116 received
three doses of recombinant hepatitis B vaccination. Seventy
percent were male, and the majority (86%) were black. Of the
116 patients who received three doses of HBV vaccination, 62
(53.4%) developed protective antibody titers. This was compa-
rable to the response rate of 50.4% in the randomly selected
220 non-HIV hemodialysis patients. Among HIV ESRD pa-
tients, the mean hemoglobin (Hgb) was higher in patients who
developed protective antibody titers (Hgb 11.61 ± 2 vs. 10.55 ±
1.86, P value <0.01). On multivariate logistic regression anal-
ysis, higher Hgb was associated with protective antibody titers
(odds ratio: 1.34, 95% CI 0.99–1.72). Seventy percent of the
HIV-infected responders maintained protective antibody titers
6 months after vaccination.
Conclusion. Hepatitis B vaccination should be offered
to all HIV-infected ESRD patients because over half of
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the patients with HIV and ESRD can develop protective
antibodies.
Hepatitis B virus (HBV) is acquired primarily as a
blood-borne infection. Patients with end-stage renal dis-
ease (ESRD) on hemodialysis (HD) are at high risk of
HBV infection. Despite marked decrease in incidence of
newly acquired HBV infection among chronic hemodial-
ysis patients in the United States after implementation of
recommendations for the control of hepatitis B in dial-
ysis centers in 1977, outbreaks of HBV continue to oc-
cur in these patients due to deficiencies in recommended
infection control practices [1–5]. Unlike healthy individ-
uals, those with ESRD and HBV infection usually have
mild asymptomatic infections, but a large proportion be-
come chronic carriers, probably due to an immune defect,
and remain highly infectious [6]. Therefore, hepatitis B
vaccine has been recommended for both hemodialysis
patients and staff members since the vaccine became
available in 1982 [7]. However, compared with adults with
normal immune status, the proportion of hemodialysis
patients who develop a protective antibody response af-
ter vaccination (even with higher doses) is lower [8–15].
Immune dysfunction caused by a metabolic monocyte de-
fect related to ESRD is thought to be the reason for this
unresponsiveness [16, 17].
Human immunodeficiency virus (HIV) infection con-
tinues to be an important cause of ESRD. Recent in-
formation from the United States Renal Data System
database and CDC surveillance data suggests that 1.4%
to 1.5% of all HD patients are infected with HIV [4, 18].
Immunization for hepatitis B in HIV-infected HD pa-
tients is more important because not only does HBV in-
fection occur more frequently with HIV infection due to
common route of infection, but it is much more likely
to result in chronic infection [19]. However, some small
studies have reported a suboptimal response to HBV vac-
cination in HIV-infected patients [20–28]. To determine
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if the suboptimal response to HBV vaccination in HD
patients is further exacerbated by HIV infection, we eval-
uated development of protective antibodies to HBV vac-
cination in these patients.
METHODS
We performed a retrospective cohort study of pa-
tients undergoing long-term HD at the U.S.-based dial-
ysis facilities of Gambro Corporation, North America,
from January 1990 to December 2002. The primary study
population consisted of all adult (>18 years) HD pa-
tients that were infected with HIV. A random sample of
1000 hemodialysis patients during the same period was
also identified from Gambro Corporation database and
served as control patients. Only patients who received
three doses of HBV vaccination were selected for fur-
ther analysis. Demographic and laboratory information
obtained closest to the time of vaccination was recorded.
The date of starting dialysis and the date of death (if prior
to January 2002) were recorded. Information on hep-
atitis B surface antibodies (anti-HBs) was noted one or
more months after the third dose of hepatitis vaccination.
Anti-HBs levels were measured using in vitro enzyme im-
munoassay (EIA) ET1-AB-AUK PLUS (DiaSorin Diag-
nostics, Still Water, MN, USA) Follow-up information on
anti-HBs titers was also obtained on patients who devel-
oped a positive response. For survival analyses, the data
were censored on December 31, 2002.
Statistical analysis
Patients who had an increase in anti-HBs titers
≥10 mIU/L after one month of receiving three doses of
hepatitis vaccination were considered as responders. The
nominal variables were converted to binary variables to
indicate presence or absence. A descriptive analysis was
used to graph all variables. The summary statistics and
correlations were computed to continuous variables. The
association of protective antibodies for hepatitis B was
then estimated with a logistic regression model based
on maximum likelihood estimation. The chi-square and
Fisher exact test to associate protective antibodies with
discrete variables were computed. Student t test was used
to compare mean values between patients with and with-
out protective antibodies. The Kaplan-Meier method was
used to estimate the survival of HIV-infected dialysis pa-
tients. The log-rank test was used to compare cumulative
survival among these patients stratified by response to
HBV vaccination. A Cox proportional hazards model was
used to evaluate effect of age, gender, race, hemoglobin,
serum albumin, urea reduction ratio, and response to
HBV vaccination on survival in HIV-infected patients.
The reported P values in the Cox model are based on the
Wald test. All reported P values are two-sided, and the
significant difference was defined as P < 0.05. All values
Table 1. Characteristics of HIV ESRD patients (HBV vaccination
≥3 doses)
Total (N = 116)
Age 44.7 ± 12
Sex
Males 81 (69.8%)
Females 35 (30.2%)
Race
White 10 (8.7%)
Black 99 (86.1%)
Hispanic 6 (5.2%)
Hemoglobin mg/dL 11.11 ± 1.99
URR% 67 ± 12
Albumin g/dL 3.63 ± 0.53
Year of vaccination
≤1996 26 (22.4%)
>1996 90 (77.6%)
Mean ± SD.
reported are mean ± SD unless otherwise specified. The
data analysis was done using SAS system for Windows,
version 8e (SAS Institute, Cary, NC, USA). The Human
Subject Research Committee of the University of Texas
Medical Branch, Galveston institutional review board,
approved the study.
RESULTS
We identified 347 HIV-infected HD patients. Of these,
171 received ≥3 doses of HBV vaccination. The vac-
cination protocol used was Engerix-BTM (SmithKline
Beecham Biologicals, Philadelphia, PA, USA) 40 lg/2 mL
given intramuscularly (60% patients), or Recombivax
HBTM (Merck & Company, Inc., West Point, PA, USA)
40 lg intramuscularly (40% patients) on a schedule of 0,
1, 6 months. Of these 171 patients, complete information
on anti-HBs was available in 116 patients. The majority
of the HIV-infected patients were black (86%), and 70%
were males. Table 1 shows the demographic characteris-
tics and laboratory data at the time of vaccination of these
116 patients. Sixty-two of these 116 patients developed
anti-HBs levels ≥10 IU/L, accounting for a response rate
of 53.4%. In the control (non-HIV) group, 362 received
three doses of HBV vaccination (25% Engerix- BTM and
75% Recombivax HBTM); however, complete informa-
tion on follow-up Anti-HBs was available in only 220
patients. Of these 220 patients, 111 (50.5%) responded to
the vaccination. The control group of patients was older
than HIV ESRD patients (mean age 56.4 ± 14.6 vs. 44.7 ±
12.03, respectively, P value < 0.03).
Among HIV ESRD patients, the hemoglobin level of
responders was significantly higher compared with pa-
tients who did not respond (11.6 ± 2 vs. 10.5 ± 1.86 mg/dL,
respectively; Table 2). On multivariate logistic regression
analysis, a higher hemoglobin level was the only variable
associated with anti-HBs levels ≥10 mIU/L (Table 3).
Sex, race, age, urea reduction ratio, and albumin levels
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Table 2. Comparison of HIV and non-HIV ESRD responders and nonresponders to HBV vaccination
HIV+ (N = 116) Non-HIV (N = 220)
Total Nonresponders (N = 54) Responders (N = 62) P value Nonresponders Responders P value
Age years 43. 9 ± 11.8 45. 39 ± 12.3 0.54 58.44 ± 14.3 54.37 ± 14.74 0.03
Sex
Male 40 (74.1%) 41 (66.1%) 57 (52.3%) 54 (48.6%)
Female 14 (25.9%) 21 (33.9%) 0.27 52 (47.7%) 57 (51.4%) 0.58
Race
White 6 (11.3%) 4 (6.5%) 0.38 28 (25.7%) 20 (18%) 0.11
Black 43 (81.1%) 56 (90.3%) 51 (46.8%) 64 (57.7%)
Hispanic 4 (7.5%) 2 (3.2%) 12 (11%) 17 (15.3%)
Other 1 (0.1%) 0 18 (16.5%) 10 (9%)
Hemoglobin mg/dL 10.55 ± 1.86 11.6 ± 2 0.01 11.66 ± 1.41 11.60 ± 1.43 0.96
URR% 67 ± 0.14 67 ± 0.09 0.72 73 ± 0.07 72 ± 0.07 0.41
Albumin g/dL 3.59 ± 0.48 3.66 ± 0.56 0.55 3.80 ± 0.36 3.88 ± 0.43 0.11
Year of vaccination
Pre-HAART (≤1996) 11 (20.4%) 15 (24.2%) 0.62 N/A N/A
Post-HAART (>1996) 43 (79.6%) 47 (75.8%)
N/A, not applicable. Mean ± SD.
Table 3. Univariate and multivariate logistic regression analysis showing association of responders (anti-HBS ≥10/mIU) with various covariates
in HIV-infected hemodialysis patients
Total Univariate (95% CI) P value Multivariate (95% CI) P value
Age year increase 1.01 (0.98 1.04) 0.53 1.02 (0.98–1.07) 0.36
Sex
Male 1.00 0.27 1.00 0.67
Female 1.58 (0.70–3.57) 1.26 (0.43–3.71)
Race
Black 1.00 0.16 1.00 0.09
Non-black 0.46 (0.16–1.37) 0.30 (0.07–1.26)
Year of vaccination
≤1996 1.00 0.62
>1996 0.80 (0.33–1.94)
Hemoglobin g/dL increase 1.34 (1.04–1.71) 0.02 1.31 (0.99–1.72) 0.05
URR% increase 0.93 (0.02–5.38) 0.97
Albumin g/dL increase 1.29 (0.55–3.03) 0.55 0.92 (0.33–2.56) 0.87
were not associated with response rate to HBV vaccina-
tion. We also compared the response rate of HIV ESRD
patients prior to ≤1996 and after 1996 when highly ac-
tive antiretroviral therapy (HAART) became available.
Surprisingly, the response rate to HBV vaccination in the
pre-HAART era was better than the HAART era [57.6%
(15/26) vs. 47% (47/99), respectively] (Table 2). However,
the number of patients who received HBV vaccination
prior to 1996 was small. Of the 62 HIV-infected patients
that responded to HBV vaccination, the follow-up titers
of anti-HBs at 6 months or more were available in 34
patients. Ten (29.5%) of these 34 patients had a decline
in the titers to unprotective levels, but 24 (70.5%) main-
tained titers ≥10 mIU/L at 6 months. The rate of decline
of protective antibody titers was slower in 80 control re-
sponders, for whom follow-up titers were available after
6 months. Sixty-five (81.2%) of these 80 patients had pro-
tective anti-HBs levels 6 or more months after completing
vaccination.
Of the 116-HIV infected patients, hepatitis C antibody
was checked in 43, and 13 (30%) were positive. Twelve
(40%) of the HCV-negative patients and 7 (54%) of the
HCV-positive patients had protective levels of anti-HBs.
The association between hepatitis C and anti-HBs was
not statistically significant.
Interestingly, Kaplan-Meier analysis revealed that
HIV ESRD responders to HBV vaccination had a better
survival than nonresponders (Fig. 1). However, in Cox-
proportional hazard analysis, only younger age and high
serum albumin levels were associated with better sur-
vival. Although there was a trend towards better survival
of HIV ESRD responders compared to nonresponders
(hazard ratio: 0.42, 95% CI 0.17–1.07), this was not sta-
tistically significant (P value = 0.07).
DISCUSSION
To our knowledge, no prior study has addressed the
important issue of the efficacy of vaccination in HIV-
infected ESRD patients. Interestingly, a response rate of
54% in HIV-infected HD patients was better compared
with response rate of 50% in a randomly selected group
of HD patients who received the same regimen of vacci-
nation. This response rate of 50% in control (non-HIV)
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Fig. 1. Kaplan-Meier estimates of survival of
HIV-infected hemodialysis (HD) responders
(positive) and nonresponders (negative) to
hepatitis B vaccination (log-rank P value =
0.0006). Number of patients at various time
periods is shown in the table below. However,
on Cox-proportional hazard analysis this find-
ing was not statistically significant (hazard ra-
tio: responders vs. nonresponders 0.42, 95%
confidence interval 0.17–1.07, P value 0.07).
HD patients is consistent with several other studies that
have also reported that only 34% to 88% of patients who
receive the three doses of HBV develop protective anti-
bodies [8–11].
Several factors could account for an almost equal re-
sponse to HBV vaccination in HIV and non-HIV ESRD
patients in our study. Most, but not all studies on HIV-
infected patients without renal failure have reported im-
paired immune response to vaccination [20–28]. Huang
et al found that HIV-infected homosexual men, asymp-
tomatic or with persistent generalized lymphadenopa-
thy, were able to mount appropriate antibody responses
to influenza and pneumococcal vaccine similar to HIV-
seronegative men [28]. Reports of the influence of CD4
cell count on the response to HBV vaccination in HIV-
infected patients have also been inconsistent. Rey et al
found a positive correlation of anti-HBs titers following
HBV vaccination with CD4 count [24]. In contrast, Wong
et al found a trend toward lower CD4 counts among
HIV-infected patients who responded to HBV vaccina-
tion [20]. Little is known about the basic immunologic
response to HBs Ag following vaccination, apart from
expected cooperation between the two areas of the hu-
man immune response [29]. Therefore, relatively crude
index of T-cell phenotype enumeration may not be the
best predictor of response. Although the information on
total CD4 count at the time of vaccination was not avail-
able to us, a better response rate to HBV vaccination in
pre-HAART (57.6%) than HAART (47%) era supports
that total CD4 count may not be very important in the
response to HBV vaccination.
More importantly, the better response rate in HIV
ESRD patients compared with randomly selected con-
trol patients could be due to the fact that HIV ESRD pa-
tients were significantly younger (mean age HIV-infected
vs. control patients: 44.6 ± 12.0 vs. 56.4 ± 14.6, P value
< 0.04). Several studies have shown that major determi-
nant of HBV vaccine response is age, with the proportion
of persons developing a protective antibody response de-
clining to 84% among adults aged >40 years and 75% by
age 60 years [31, 32]. Similarly, Peces et al, in a prospec-
tive study with 80 HD patients, found that 100% of the
patients (younger than 40 years) developed protective
antibodies to HBV vaccination compared with only 74%
in patients older than 60 years [33].
Some, but not all, studies have suggested that protec-
tive antibody titers may fall rapidly after vaccination in
HIV-infected patients [27, 34]. Ray et al obtained a to-
tal response rate of 90% in HIV-infected patients after
giving three additional doses of HBV vaccination to non-
responders. However, only 10/17 (58.8%) patients had
protective antibodies after a year [27]. Manicalgi reported
a response rate of 62% in 21 young HIV-infected heroin
addicts. However, 70% of these patients maintained pro-
tective antibody titers after one year of follow-up [35]. We
found that 70% of the responders maintained protective
anti-HBs titers 6 or more of months after HBV vacci-
nation. The difference in the decline in the protective
antibodies in the above studies could be due to different
HBV vaccines and regimens used, and/or the peak level
of anti-HBs obtained.
It is well know that hemodialysis patients on erythro-
poietin with higher hemoglobin have a better response
rate to HBV vaccination [36–38]. Although we did not
have information on erythropoietin doses in our patients,
we did find that patients with higher (mg/dL) hemoglobin
levels had a 34% greater chance of having protective anti-
body levels. Because the prevalence of anemia is higher in
patients with AIDS compared to patients with early stage
of HIV infection, hemoglobin levels may also reflect stage
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Table 4. Cox-proportional hazard analysis of survival of HIV ESRD
patients
Adjusted Hazard
Risk factor Ratio (95% CI) P value
Anti-HBs 0.068
Negative 1.00
Positive 0.42 (0.17–1.07)
Age per year increase 1.04 (1.00–1.08) 0.03
Gender
Female 1.00
Male 1.05 (0.42–2.64) 0.91
Race
Other 1.00
Black 1.44 (0.42–5.00) 0.56
Hemoglobin mg/dL change 1.14 (0.91–1.42) 0.24
Serum albumin g/dL increase 0.30 (0.12–0.75) 0.009
URR% increase 0.53 (0.22–1.29) 0.16
and severity of HIV infection and, henceforth, immune
response to HBV vaccination.
Interestingly, we found that HBV vaccine responders
had a better survival than nonresponders. This survival
benefit was partially lost in the final Cox-proportional
hazard model; the responders had a 58% better survival
rate (Table 4). Although we did not have information
on CD4 counts, the better survival could be due the fact
that response to HBV vaccination may reflect the degree
of immunosuppression in these patients. Several studies
have shown that the stage of HIV infection and albu-
min levels are predictors of long-term survival of HIV-
infected patients [39, 40]. Consistent with these studies,
we also found that hypoalbuminemia was associated with
higher risk of death (Table 4).
The major shortcomings of our study is that the infor-
mation on CD4 counts, plasma viral loads, and antiretro-
viral therapy were not available to us in these patients to
determine if immune response to HBV vaccination was
related to these factors. The effect of these factors, how-
ever, is attenuated by the fact that renal disease in HIV
infection develops in advanced stage of HIV infection
[41]. The other factor that could have altered results in
our study is that patients with severe immunosuppression
and advanced AIDS may not have been offered or com-
pleted a full course of vaccination due to high mortality
rate. This could have lead to overestimation of response
rate to HBV vaccination. The reasons for underutiliza-
tion of HBV vaccination in control patients compared
with HIV infected patients (36% vs. 50%) were not avail-
able from the database. CDC surveillance of hemodialy-
sis facilities found that, although during 1983 to 2001 the
percentage of patients who received at least three doses
of HBV increased from 5.4% to 59.8%, the underutiliza-
tion of HBV vaccination was common, as only 42.8%
to 69.5% of patients among various ESRD networks re-
ceived HBV vaccination [42]. We can only speculate that
nephrologists may have utilized HBV vaccination more
frequently in HIV-infected patients, realizing that these
patients are at a higher risk of hepatitis B.
CONCLUSION
Over half of the HIV-infected patients on HD can de-
velop and maintain protective antibody titers to HBV
vaccination. Therefore, HBV vaccination should be of-
fered to these patients, although more frequent screen-
ing for anti-HBs titer may be required than the annual
testing recommended for hemodialysis patients. Future
prospective studies are required to determine predictors
of immune response and strategies such as intradermal
administration, concomitant administration of erythro-
poietin or granulocyte colony stimulating factor, and
triple antigen recombinant HBV vaccines to enhance
the development of protective antibodies in response to
HBV vaccination in this high-risk group of patients.
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